MoneyGram Reports Strong Start to Fourth Quarter with 10th Consecutive Month of Triple-Digit Growth in MGO

MoneyGram achieved 150% year-over-year cross-border transaction and revenue growth for October in its direct-to-consumer digital business, MGO

PR Newswire

DALLAS, Nov. 12, 2020 /PRNewswire/ — MoneyGram International, Inc. (NASDAQ: MGI), a global leader in cross-border P2P payments and money transfers, today announced the Company delivered 150% year-over-year cross-border transaction and revenue growth for October in its direct-to-consumer digital business, MGO. This marks the tenth consecutive month of triple-digit year-over-year cross-border transaction growth in this channel.

“These results continue to demonstrate our ability to capture share as we strengthen our market position due to the success of our customer-led digital transformation,” said Alex Holmes, MoneyGram Chairman and CEO. “We are encouraged by both our strong momentum and our purpose to mobilize the movement of money, which is now more relevant than it ever has been. MoneyGram’s growth reinforces the essential role we play in our customers’ daily lives, and we’re increasingly excited about our long-term trajectory.”

Growth continues to be driven by high customer retention rates, strong consumer demand for the Company’s leading mobile app, and sends directly to bank accounts. Investments in these key areas over the past few years have enabled MoneyGram to build a modern, mobile, and customer-centric organization delivering consistent results.

“Our leading customer experience is driving these phenomenal results. Customers are choosing MoneyGram over other options because the app is easier to use, faster, and more affordable,” said Kamila Chytil, MoneyGram Chief Operating Officer and leader of the Company’s digital business. “As we execute our strategy to build upon our momentum in the market, we expect our direct-to-consumer digital business to continue to deliver profitable growth.”

The Company’s impressive October results come on the heels of strong third quarter results where MoneyGram reported that Operating Income increased 123% and Adjusted EBITDA increased 33% year-over-year. Those results were driven by the profitability of the digital business, the resurgence of growth from the money transfer business, the agile management of the Company throughout the crisis, and operational efficiencies from the Company’s digital transformation.

About MoneyGram International, Inc.
MoneyGram is a global leader in cross-border P2P payments and money transfers. Its consumer-centric capabilities enable family and friends to quickly and affordably send money in more than 200 countries and territories, with 81 now digitally enabled.

MoneyGram leverages its modern, mobile, and API-driven platform and collaborates with the world’s leading brands to serve millions of people each year through both its walk-in business and its direct-to-consumer digital business.

With a strong culture of innovation and a relentless focus on utilizing technology to deliver the world’s best customer experience, MoneyGram is leading the evolution of digital P2P payments.

For more information, please visit moneygram.com and follow @MoneyGram.

Media Contact:

Stephen Reiff

[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/moneygram-reports-strong-start-to-fourth-quarter-with-10th-consecutive-month-of-triple-digit-growth-in-mgo-301172094.html

SOURCE MoneyGram

American Dream Launches First-Ever Wish Week

Thanksgiving Holiday Extended to One Full Week of Retail Promotions, Surprise-and-Delight Attraction Giveaways to Make Dreams Come True

East Rutherford, New Jersey, Nov. 12, 2020 (GLOBE NEWSWIRE) — This year, American Dream continues to reinvent the entertainment, shopping, and dining experience by expanding the Black Friday start of the holiday shopping season from one day to eight and making dreams come true. Working closely with its brand partners and attractions, American Dream’s Wish Week will bring holiday magic to the traditional Thanksgiving season and create new memories for guests.

 

Beginning November 23 through November 30, guests visiting American Dream will be treated to special surprises, magical giveaways, and one-of-a-kind experiences all week.  To provide a safe experience throughout Wish Week, and all season long, American Dream’s #dreamsafe initiative, which launched together with Hackensack Meridian Health, sets the standard in cleanliness and health and safety protocols. The property will ease the common stresses of the season by offering online to offline gifting consultations, curated gift guides, and curbside pickup, among others.

 

American Dream will have extended hours during Wish Week and all throughout the holiday season. Visit www.americandream.com for its holiday operating hours. American Dream will be closed on Thanksgiving Day, November 26.

 

“At American Dream, we’re always re-thinking, re-inventing, and putting a fresh spin on conventional experiences,” said Mark Ghermezian, co-CEO of American Dream.  “This year, we’re moving away from the traditional one-day Black Friday holiday and expanding to eight magical days, giving families the chance to experience American Dream at a time most convenient for them,” he added.  

 

There are surprises around every corner—here’s just a sneak peek at what’s in store at American Dream’s Wish Week (and all holiday season):

  • Monday, November 23: Love’s Got to Give!: With more than 500 poinsettias in the Winter Garden Court, a winter wonderland of 550 snowflakes over The Rink, more than 100 holiday trees and 12 Photo Booths throughout, American Dream is sure to be the most Instagrammable backdrop to capture all your holiday moments.  
  • Tuesday, November 24: Wish for Fun and Sun: We’ve brought the sunshine indoors at American Dream. Don’t miss our splash-worthy Wish Wave Pool at DreamWorks Water Park, complete with a DJ and dance music for some serious–and safely distanced–family fun. While you’re here, be sure to reserve one of our Jonathan Adler-designed private cabanas! Whether shopping our Resort collections throughout our stores, or cooling down on tropical frozen treats, American Dream is the ultimate staycation destination this holiday season.
  • Wednesday, November 25: Winter Wishes: It’s cold outside, so bundle up and enjoy all the warmth of the holiday season at American Dream. Whether you choose to hit the slopes at Big SNOW, take a spin around The Rink, or shop our curated collections of sparkly jewelry, cozy, layered knits and outerwear, American Dream makes winter wishes come true.
  • Thursday, November 26: American Dream will be closed on Thanksgiving Day so that our Dream Makers can celebrate the holiday with their loved ones.
  • Friday, November 27: The Wish List: Holiday wishes, granted. Today, we’re all about making the biggest day in shopping even better, as only American Dream can do. Shop our Curated Collections on our online holiday hub. Now, isn’t that dreamy?
  • Saturday, November 28: Celebrating Our Small Businesses: In celebration of Small Business Saturday, please visit our unique mix of retail and dining partners that represent the dozens of small, independent businesses at American Dream. Look for special signs throughout American Dream indicating where these businesses are located and support the local businesses that are integral to our community.
  • Sunday, November 29
    :  Nickelodeon’s “Nickmas Universe” Opening: Mark your calendars; you don’t want to miss out on this action-packed celebration! Join us for the opening of “Nickmas Universe,” a holiday version of everyone’s favorite indoor theme park. Roaming Dream Makers will be on hand to provide bottles of water, coloring books and other treats to our guests. Shhhhh—some guests will be randomly selected to win complimentary passes to Nickmas Universe.
  • Monday, November 30: Cyber (Music) Monday: Live from American Dream! Take a break from online shopping and tune in as we bring the magic of our weekly, holiday-themed performances right to your living room. Local performers–dance troupes, choirs, performance artists–will be showcased across TikTok, Instagram, and throughout our property-wide digital network with pop-up, live sets to boot.

 

* To learn about all the health and safety precautions American Dream is taking together with Hackensack Meridian Health, please visit https://www.americandream.com/dreamsafe.

 

ABOUT AMERICAN DREAM

American Dream, developed by Triple Five Group, is an unparalleled mix of world-class entertainment, retail and dining, comprising more than 3 million square feet in East Rutherford, New Jersey, just minutes away from New York City. American Dream is home to leading attractions that includes DreamWorks Water Park, Nickelodeon Universe, Big SNOW, Angry Birds Not So Mini Golf Club, The Rink, Out of This World Blacklight Mini Golf, and a curated collection of premier dining and retail stores, including flagship locations for H&M, Uniqlo and PRIMARK as well as Lululemon, Sephora, Aritzia, Zara and IT’SUGAR, the world’s first “candy department store.” For more information on American Dream and our health and safety protocols, visit www.americandream.com or follow us on Instagram @americandream. 

Attachment

Demi Halawa
American Dream
[email protected]

AB INTL GROUP Updates Progress of Film “Love Over the World” (AiBianQuanQiu) and NYC Office

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — AB International Group Corp. (OTCQB: ABQQ), an intellectual property (IP) and movie investment and licensing firm, announces update progress of its first completed film, “Love Over the World” (AiBianQuanQiu), its producer company hasn’t received screening license from China govt and any notice yet. The distributors were update to the Company: the film unable schedule to be screened on cinemas nationwide before January 2021. The Company also announced because COVID pandemics reason, its North America Operation Offices in NYC has no timetable for official launch.

About AB International Group Corp. 
AB International Group Corp. is an intellectual property (IP) and movie investment and licensing firm, focused on acquisitions and development of various intellectual property. We are engaged to acquisition and distribution of movies. The Company has a Patent License to a video synthesis and release system for mobile communications equipment, in which the technology is the subject of a utility model patent in the People’s Republic of China. The Company engages highly anticipated video streaming service targeting global multi-billion dollar and growing video streaming industry. The online service will be marketed and distributed in the world under the brand name ABQQ.tv. ABQQ.tv is expected to generate a new and profitable revenue stream immediately following its launch derived from its hybrid subscription and advertising business model.

For additional information visit www.abqqs.com 

Forward-Looking Statements 
This press release contains “forward-looking statements” that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements relating to changes to the Company’s management team and statements relating to the Company’s transformation, financial and operational performance including the acceleration of revenue and margins, and the Company’s overall strategy. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the possibility of business disruption, competitive uncertainties, and general economic and business conditions in AB International Groups markets as well as the other risks detailed in company filings with the Securities and Exchange Commission. AB International Group undertakes no obligation to update any statements in this press release for changes that happen after the date of this release.

Investor Relations Contact:
Andrew Barwicki
516-662-9461 / [email protected]  
[email protected]

Norsk Hydro: Distribution of dividends

The Board of Directors at Norsk Hydro ASA has today decided to distribute a dividend of NOK 2.6 billion based on the financial results for the 2019 financial year. This corresponds to a dividend of NOK 1.25 per share.

In February 2020, the Board decided to propose a dividend of NOK 1.25 per share for 2019, in accordance with the floor level stated in Hydro’s dividend pay-out policy.

Following the decision, the outbreak of the Covid-19 pandemic introduced significant uncertainty regarding the financial outlook for the company. The Board was therefore granted an authority at the Annual General Meeting held on 11 May 2020 to resolve distribution of dividends at a later stage at the Board’s discretion. The authority was restricted to a maximum dividend payment of NOK 1.25 per share.

The Board’s decision to distribute dividends for 2019 is based on the improved financial situation and outlook for the company.  

Shareholders registered on 16 November 2020 will be entitled to receive the dividend. The ex-dividend date is 17 November 2020, and the record date is 18 November 2020. The dividend will be distributed on 25 November 2020.

Investor contact:
Line Haugetraa
+47 41406376
[email protected]

Media contact:
Halvor Molland
+47 92979797
[email protected]

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Dr. Reddy’s Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) in the U.S. Market

Dr. Reddy’s Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL) in the U.S. Market

HYDERABAD, India & PRINCETON, N.J.–(BUSINESS WIRE)–
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL), Multiple-Dose Vials a therapeutic equivalent generic version of Quelicin® (Succinylcholine Chloride) Injection, 20 mg/mL, approved by the U.S. Food and Drug Administration (USFDA).

The Quelicin® brand and generic market had U.S. sales of approximately $74.8 million MAT for the most recent twelve months ending in September 2020 according to IQVIA Health*.

Dr. Reddy’s Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL), is available in multi-dose vials.

Please see full prescribing information including boxed warning.

https://www.drreddys.com/pi/succinylcholine-chloride.pdf

WARNING

RISK OF CARDIAC ARREST FROM HYPERKALEMIC RHABDOMYOLYSIS

There have been rare reports of acute rhabdomyolysis with hyperkalemia followed by ventricular dysrhythmias, cardiac arrest and death after the administration of succinylcholine to apparently healthy pediatric patients who were subsequently found to have undiagnosed skeletal muscle myopathy, most frequently Duchenne’s muscular dystrophy.

 

This syndrome often presents as peaked T-waves and sudden cardiac arrest within minutes after the administration of the drug in healthy appearing pediatric patients (usually, but not exclusively, males, and most frequently 8 years of age or younger). There have also been reports in adolescents.

 

Therefore, when a healthy appearing infant or child develops cardiac arrest soon after administration of succinylcholine, not felt to be due to inadequate ventilation, oxygenation or anesthetic overdose, immediate treatment for hyperkalemia should be instituted. This should include administration of intravenous calcium, bicarbonate, and glucose with insulin, with hyperventilation. Due to the abrupt onset of this syndrome, routine resuscitative measures are likely to be unsuccessful. However, extraordinary and prolonged resuscitative efforts have resulted in successful resuscitation in some reported cases. In addition, in the presence of signs of malignant hyperthermia, appropriate treatment should be instituted concurrently.

 

Since there may be no signs or symptoms to alert the practitioner to which patients are at risk, it is recommended that the use of succinylcholine in pediatric patients should be reserved for emergency intubation or instances where immediate securing of the airway is necessary, e.g., laryngospasm, difficult airway, full stomach, or for intramuscular use when a suitable vein is inaccessible (see PRECAUTIONS:Pediatric Use and DOSAGE AND ADMINISTRATION).

Quelicin® is a trademark of Hospira, Inc

*IQVIA Retail and Non-Retail MAT September 2020

RDY-0820-308

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to:www.drreddys.com

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the “Risk Factors” and “Forward-Looking Statements” sections of our Annual Report on Form 20-F for the year ended March 31, 2020. The company assumes no obligation to update any information contained herein.”

INVESTOR RELATIONS

AMIT AGARWAL [email protected]

(PH: +91-40-49002135)

MEDIA RELATIONS

APARNA TEKURI

[email protected]

(PH: +91-40- 49002446)

KEYWORDS: United States India North America Asia Pacific New Jersey

INDUSTRY KEYWORDS: Health Pharmaceutical

MEDIA:

Logo
Logo

IIROC Trading Halt – CRVC

Canada NewsWire

VANCOUVER, BC, Nov. 12, 2020 /CNW/ – The following issues have been halted by IIROC:

Company: Cross River Ventures Corp.

CSE Symbol: CRVC

All Issues: Yes

Reason: At the request of the Company Pending News

Halt Time (ET): 10:07 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) – Halts/Resumptions

PAOG Confirms CBD Pharmaceutical Partnership With New PURA Hemp Initiative

PR Newswire

SANDUSKY, Ohio, Nov. 12, 2020 /PRNewswire/ — PAO Group, Inc. (USOTC: PAOG) today confirmed a pharmaceutical and neurocritical extraction partnership with Puration, Inc. (USOTC: PURA).

PURA has acquired a 72-acre property in Farmersville, Texas as the foundation of an innovative, hemp processing plant. PURA is building partnerships to participate in the project to include a pharmaceutical and neurocritical extraction partnership with PAOG.

PURA has also established a co-packing partnership with Alkame Holdings, Inc. (USOTC: ALKM). 

Earlier this week, PURA published a multimedia presentation on the new initiative in Texas:


PURA Targets Hemp Consumer Advocates To Capture $26 Billion Market

PAOG acquired a cannabis cultivation operation from PURA earlier this year in a transaction that includes issuing PAOG shares to PURA shareholders. The target distribution ratio calls for PURA shareholders receiving one share of PAOG for every one share of PURA owned.

For more information on PAO Group, visit www.paogroupinc.com

Sign up to receive the latest updates at www.purationinc.com.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Contact:

Puration, Inc.
Brian Shibley,
[email protected]
(800) 861-1350

PAO Group, Inc.
Jim DiPrima
888-272-6472
[email protected]

 

 

Cision View original content:http://www.prnewswire.com/news-releases/paog-confirms-cbd-pharmaceutical-partnership-with-new-pura-hemp-initiative-301172084.html

SOURCE PAO Group, Inc.

Thinking about buying stock in IMAC Holdings, Advanced Micro Devices, Biocept, Li Auto, or EuroDry?

PR Newswire

NEW YORK, Nov. 12, 2020 /PRNewswire/ — InvestorsObserver issues critical PriceWatch Alerts for IMAC, AMD, BIOC, LI, and EDRY.

InvestorsObserver_Logo

To see how InvestorsObserver’s proprietary scoring system rates these stocks, view the InvestorsObserver’s PriceWatch Alert by selecting the corresponding link.

(Note: You may have to copy this link into your browser then press the [ENTER] key.)

InvestorsObserver’s PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock’s overall suitability for investment.

Cision View original content:http://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-imac-holdings-advanced-micro-devices-biocept-li-auto-or-eurodry-301172086.html

SOURCE InvestorsObserver

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zosano Pharma Corporation (ZSAN)

PR Newswire

LOS ANGELES, Nov. 12, 2020 /PRNewswire/ — The Law Offices of Frank R. Cruz reminds investors of the upcoming December 28, 2020deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Zosano Pharma Corporation (“Zosano” or the “Company”) (NASDAQ: ZSAN) securities between February 13, 2017 and September 30, 2020, inclusive (the “Class Period”).

If you are a shareholder who suffered a loss, click here to participate.

On September 30, 2020, the Company revealed that it received “a discipline review letter (DRL) from the U.S. Food and Drug Administration (FDA) in connection with the Qtrypta™ (zolmitriptan transdermal microneedle system) 505(b)(2) New Drug Application (NDA).” According to the Zosano’s press release, the FDA “raised questions regarding unexpected high plasma concentrations of zolmitriptan observed in five study subjects from two pharmacokinetic studies and how the data from these subjects affect the overall clinical pharmacology section of the application.” The FDA also “raised questions regarding differences in zolmitriptan exposures observed between subjects receiving different lots of Qtrypta in the company’s clinical trials.”

On this news, the Company’s stock price fell $0.92 per share, or 57%, to close at $0.70 per share on October 1, 2020.

On October 21, 2020, the Company disclosed receipt of a Complete Response Letter (“CRL”) from the FDA. As a result of the inconsistencies identified in the DRL, the FDA recommended that the Zosano conduct a repeat bioequivalence study between three of the lots used during development.

On this news, Zosano’s stock price fell $0.17 per share, or 27%, to close at $0.4441 per share on October 21, 2020.

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the Company’s clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) that pharmocokinetic studies submitted in connection with the Company’s NDA included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) that, as a result of the foregoing differences among patient results, the FDA was reasonably likely to require further studies to support regulatory approval of Qtrypta; (4) that, as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants’ public statements were materially false and misleading at all relevant times.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased or otherwise acquired Zosano securities during the Class Period, you may move the Court no later than December 28, 2020to request appointment as lead plaintiff in this putative class action lawsuit.  To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.  If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com.  If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

www.frankcruzlaw.com


 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/the-law-offices-of-frank-r-cruz-reminds-investors-of-looming-deadline-in-the-class-action-lawsuit-against-zosano-pharma-corporation-zsan-301171602.html

SOURCE The Law Offices of Frank R. Cruz, Los Angeles

IT Tech Packaging, Inc. Announces Third Quarter 2020 Financial Results

Company to Host Earnings Conference Call on Friday, November 13, 2020, at 8:00 am ET

PR Newswire

BAODING, China, Nov. 12, 2020 /PRNewswire/– IT Tech Packaging, Inc. (NYSE American: ITP) (“IT Tech Packaging” or the “Company”), a leading manufacturer and distributor of diversified paper products in North China, today announced its unaudited financial results for the third quarter ended September 30, 2020.

Third Quarter 2020 Unaudited Financial Results


 For the Three Months Ended September 30,


 ($ millions)


2020


2019


 % Change

 Revenues

33.36

32.94

1.3%

 Regular Corrugating Medium Paper (“CMP”)*

19.55

19.33

1.1%

 Light-Weight CMP**

5.08

5.02

1.2%

 Offset Printing Paper

6.13

7.04

-12.9%

 Tissue Paper Products

2.38

1.55

53.4%

  Face Masks

0.22

NM

NM

 Gross profit

2.57

5.37

-52.2%

 Gross profit (loss) margin

7.7%

16.3%

-8.6 pp****

 Regular Corrugating Medium Paper (“CMP”)*

6.4%

14.7%

-8.3 pp****

 Light-Weight CMP**

9.4%

15.9%

-6.5 pp****

 Offset Printing Paper

18.9%

33.3%

-14.4pp****

 Tissue Paper Products***

-14.5%

-38.9%

24.4 pp****

 Face Masks

11.1%

NM

NM

 Operating income

0.18

3.35

-94.7%

 Net income

-0.52

2.34

-122.3%

 EBITDA

3.57

7.11

-49.8%

 Basic and Diluted earnings (loss) per share

-0.02

0.11

-118.2%


 * Products from PM6


 ** Products from PM1


 *** Products from PM8 and PM9


 **** pp represents percentage points

 

  • Revenue slightly increased by 1.3% to $33.4 million, primarily attributable to an increase in sales volume of tissue paper products and CMP products.
  • Gross profit decreased by 52.2% to $2.6 million. Total gross margin decreased by 8.6 percentage point to 7.7%.   
  • Income from operations was $0.2 million, compared to income from operations of $3.4 million for the same period of last year.
  • Net loss was $0.5 million, or loss of $0.02 per basic and diluted share, compared to net income of $2.3 million, or $0.11 per basic and diluted share, for the same period of last year.
  • Earnings before interest, taxes, depreciation and amortization (“EBITDA”) decreased by 49.8% to $3.6 million.

Mr. Zhenyong Liu, Chairman and Chief Executive Officer of the Company, commented, “We continued to make improvements in sales volume for this quarter as our paper products business, along with the whole industry, recovered from the pandemic. Our total revenue increased to 33.4 million and our tissue paper products grew 53.4% in revenue with total sales volume of 74,126 tonnes for this quarter. Sales volumes for CMPs and offset printing paper continued quarter-on-quarter growth and rebounded to the same level as last year. Our ASPs recording a 10.4% sequential increase from Q2 2020, experienced slight decreases compared to the Q3 2019.

“The Chinese government updated the Ban on Free Plastic Bags in 2020 and as the specific restrictions are implemented nationwide, paper packing products are expected to become the main substitute of plastic packages under the requirements, involving sectors such as catering takeout, supermarket retailing, logistics and express delivery. According to Huachuang Securities’ market analysis on substitute demand for cardboard paper in the aforementioned areas, the market demand is expected to be 4.91 million tonnes. As such, the company will take full advantage of the market opportunities brought by the substitute demand for paper packages.”

Revenue

For the third quarter of 2020, total revenue increased by $0.4 million, or 1.3%, to $33.4 million from $32.9 million for the same period of last year. The increase in total revenue was mainly due to increase in sales volume of tissue paper products, CMP and face masks.

The following table summarizes revenue, volume and ASP by product for the third quarter of 2020 and 2019, respectively:


For the Three Months Ended September 30,


2020


2019


Revenue ($’000)


Volume (tonne)


ASP ($/tonne)


Revenue ($’000)


Volume (tonne)


ASP ($/tonne)

Regular CMP

19,554

48,107

406

19,332

47,487

407

Light-Weight CMP

5,076

12,884

394

5,017

12,721

394

Offset Printing Paper

6,126

10,280

596

7,038

10,198

690

Tissue Paper Products

2,380

2,855

834

1,551

1,840

843


Total


33,136


74,126


447


32,938


72,246


456


Revenue ($’000)


Volume (thousand pieces)


ASP ($/thousand pieces)


Revenue ($’000)


Volume ($/thousand pieces)


ASP ($/thousand pieces)

Face Masks

221

3,576

62

 NM 

 NM 

 NM 

Revenue from CMP, including both regular CMP and light-Weight CMP, increased by $0.3 million, or 1.2%, to $24.6 million and accounted for 73.8% of total revenue for the third quarter of 2020, compared to $24.3 million, or 73.8% of total revenue, for the same period of last year. The Company sold 60,991 tonnes of CMP at an ASP of $404/tonne in the third quarter of 2020, compared to 60,209 tonnes at an ASP of $404/tonne in the same period of last year.

Of the total CMP sales, revenue from regular CMP increased by $0.2 million, or 1.1%, to $19.6 million, resulting from sales of 48,107 tonnes at an ASP of $406/tonne, during the third quarter of 2020, compared to revenue of $19.3 million, resulting from sales of 47,487 tonnes at an ASP of $407/tonne, for the same period of last year. Revenue from light-weight CMP increased by $0.06 million, or 1.2%, to $5.1 million, resulting from sales of 12,884 tonnes at an ASP of $394/tonne for the third quarter of 2020, compared to revenue of $5.0 million, resulting from sales of 12,721 tonnes at an ASP of $394/tonne for the same period of last year.

Revenue from offset printing paper decreased by $0.9 million, or 12.9%, to $6.1 million for the third quarter of 2020, from $7.0 million for the same period of last year. The Company sold 10,280 tonnes of offset printing paper at an ASP of $596/tonne in the third quarter of 2020, compared to 10,198 tonnes at an ASP of $690/tonne in the same period of last year.

Revenue from tissue paper products increased by $0.8 million, or 53.4%, to $2.4 million, resulting from sales of 2,855 tonnes at an ASP of $834/tonne, for the third quarter of 2020, compared to revenue of $1.6 million, resulting from sales of 1,840 tonnes at an ASP of $843/tonne for the same period of last year.

Revenue generated from selling face masks was $0.2 million for the third quarter ended September 30, 2020. The Company sold 3,576 thousand pieces of face masks in the third quarter of 2020.

Gross Profit and Gross Margin

Total cost of sales increased by $3.2 million, or 11.7%, to $30.8 million for the third quarter of 2020 from $27.6 million for the same period of last year. For paper products, overall cost of sales per tonne was $415 for the third quarter of 2020, compared to $382 for the same period of last year. The increase in overall cost of sales was mainly due to the increased manufacturing overhead costs and increased material costs, specifically higher average unit purchase costs of recycled paper board and recycled white scrap paper in the third quarter of 2020. Average unit purchase costs of recycled paper board and recycled white scrap paper, major raw material used for production, was approximately $251/tonne and $297/tonne, respectively, for the third quarter of 2020, compared to $200/tonne and $258/tonne, respectively, for the same period of last year. Costs of sales per tonne for regular CMP, light-weight CMP, offset printing paper, and tissue paper products were $380, $357, $483, and $955, respectively, for the third quarter of 2020, compared to $347, $332, $461 and $1,171, respectively, for the same period of last year. Total gross profit was $2.6 million for the third quarter of 2020, compare to the gross profit of $5.4 million for the same period of last year as a result of factors described above. Overall gross margin was 7.7% for the third quarter of 2020, compared to 16.3% for the same period of last year. Gross profit (loss) margins for regular CMP, light-weight CMP, offset printing paper, tissue paper products and face mask products were 6.4%, 9.4%, 18.9%, -14.5% and 11.1%, respectively, for the third quarter of 2020, compared to 14.7%, 15.9%, 33.3%,-38.9% and nil, respectively, for the same period of last year.

Selling, General and Administrative Expenses

Selling, general and administrative expenses (“SG&A”) increased by $0.4 million, or 18.1%, to $2.4 million for the third quarter of 2020 from $2.0 million for the same period of last year. The increase was mainly due to additional expenditure on investment relation activities (e.g. consultancy, board meeting etc.) and reversal of over-provision of lease expenses for the lands of Heibei Tengsheng in the third quarter of 2019. 

Income (loss) from Operations

Income from operations was $0.2 million for the third quarter of 2020, compared to income from operations of $3.3 million for the same period of last year. The decrease in income from operations was primarily due to increased SG&A expenses and decreased gross profit this quarter as discussed above. Operating margin was 0.5% for the third quarter of 2020, compared to operating margin of 10.2% for the same period of last year.

Net Income (Loss)

Net loss was $0.5 million, or $0.02 loss per basic and diluted share, for the third quarter of 2020, compared to net income of $2.3 million, or $0.11 per basic and diluted share, for the same period of last year.

EBITDA

EBITDA was $3.6 million for the third quarter of 2020, compared to $7.1 million for the same period of last year.

Note 1: Non-GAAP Financial Measures

In addition to our U.S. GAAP results, this press release includes a discussion of EBITDA, a non-GAAP financial measure as defined by the Securities and Exchange Commission (“SEC”). The Company defines EBITDA as net income before interest, income taxes, depreciation and amortization. EBITDA is a key measure used by management to evaluate our results and make strategic decisions. Management believes this measure is useful to investors because it is an indicator of operational performance. Because not all companies use identical calculations, the Company’s presentation of EBITDA may not be comparable to similarly titled measures of other companies, and should not be viewed as an alternative to measures of financial performance or changes in cash flows calculated in accordance with the U.S. GAAP.


Reconciliation of Net Income to EBITDA


(Amounts expressed in US$)


 For the Three Months Ended September 30,


 ($ millions)


2020


2019

 Net income (loss)

-0.52

2.34

 Add: Income tax

0.03

0.77

         Net interest expense

0.26

0.24

         Depreciation and amortization

3.81

3.76

 EBITDA


3.57


7.11

 

Nine Months Ended September 30, 2020 Financial Results


 For the Nine Months Ended September 30,


 ($ millions)


2020


2019


 % Change

 Revenues

68.46

84.01

-18.5%

 Regular Corrugating Medium Paper (“CMP”)*

42.65

52.44

-18.7%

 Light-Weight CMP**

11.59

13.69

-15.3%

 Offset Printing Paper

7.39

13.27

-44.3%

 Tissue Paper Products

5.77

4.60

25.3%

  Face Musks

1.07

NM

NM

 Gross profit

4.96

8.09

-38.7%

 Gross profit (loss) margin

7.2%

9.6%

-2.4 pp****

 Regular Corrugating Medium Paper (“CMP”)*

7.3%

8.4%

-1.1 pp****

 Light-Weight CMP**

11.2%

7.1%

4.1 pp****

 Offset Printing Paper

19.7%

29.8%

-10.1 pp****

 Tissue Paper Products***

-24.8%

-27.0%

2.2 pp****

 Face Masks

49.5%

NM

NM

 Operating income (loss)

-3.49

0.71

-593.4%

 Net income

-3.94

0.07

-6110.9%

 EBITDA

7.20

10.68

-32.6%

 Basic and Diluted earnings (loss) per share

-0.15

0.003

-5191.4%


 * Products from PM6


 ** Products from PM1


 *** Products from PM8 and PM9


 **** pp represents percentage points

Revenue

For the nine months ended September 30, 2020, total revenue decreased by $15.5 million, or 18.5%, to $68.5 million from $84.0 million for the same period of last year. The decrease in total revenue was mainly due to decrease in sales volume of Regular CMP, offset printing paper and decrease in ASPs over all paper products categories. The following table summarizes revenue, volume and ASP by product for the nine months ended September 30, 2020 and 2019, respectively:


For the Nine Months Ended September 30,


2020


2019


Revenue ($’000)


Volume (tonne)


ASP ($/tonne)


Revenue ($’000)


Volume (tonne)


ASP ($/tonne)

Regular CMP

42,648

#

108,874

392

52,440

121,774

431

Light-Weight CMP

11,594

30,384

382

13,693

32,728

418

Offset Printing Paper

7,389

12,463

593

13,275

18,757

708

Tissue Paper Products

5,766

6,923

833

4,600

4,697

979


Total


67,397


158,644


425


84,008


177,956


472


Revenue ($’000)


Volume (thousand pieces)


ASP ($/thousand pieces)


Revenue ($’000)


Volume ($/thousand pieces)


ASP ($/thousand pieces)

Face Masks

1,067

9,856

108

 NM 

 NM 

 NM 

Revenue from CMP, including both regular CMP and light-Weight CMP decreased by $11.9 million, or 18%, to $54.2 million, and accounted for 79.2% of total revenue for the first nine months of 2020, compared to $66.1 million, or 78.7% of total revenue for the same period of last year. The Company sold 139,258 tonnes of CMP at an ASP of $390/tonne in the first nine months of 2020, compared to 154,502 tonnes at an ASP of $428/tonne in the same period of last year.

Of the total CMP sales, revenue from regular CMP decreased by $9.8 million, or 18.7%, to $42.6 million, resulting from sales of 108,874 tonnes at an ASP of $392/tonne during the first nine months of 2020, compared to revenue of $52.4 million, resulting from sales of 121,774 tonnes at an ASP of $431/tonne for the same period of last year. Revenue from light-weight CMP decreased by $2.1 million, or 15.3%, to $11.6 million, resulting from sales of 30,384 tonnes at an ASP of $382/tonne for the first nine months of 2020, compared to revenue of $13.7 million, resulting from sales of 32,728 tonnes at an ASP of $418/tonne for the same period of last year.

Revenue from offset printing paper decreased by $5.9 million, or 44.3%, to $7.4 million for the first nine months of 2020 from $13.3 million for the same period of last year. The Company sold 12,463 tonnes of offset printing paper at an ASP of $593/tonne in the first nine months of 2020, compared to 18,757 tonnes at an ASP of $708/tonne in the same period of last year.

Revenue from tissue paper products increased by $1.2 million, or 25.3%, to $5.8 million, resulting from sales of 6,923 tonnes at an ASP of $833/tonne, for the first nine months of 2020, compared to revenue of $4.6 million, resulting from sales of 4,697 tonnes at an ASP of $979/tonne for the same period of last year.

Revenue generated from selling face masks was $1.1 million for the nine months ended September 30, 2020. The Company sold 9,856 thousand pieces of face masks for the first nine months of 2020.

Gross Profit and Gross Margin

Total cost of sales decreased by $12.4 million, or16.3%, to $63.5 million for the first nine months of 2020 from $75.9 million for the same period of last year. The decrease in overall cost of sales was mainly due to the decreased sales volume of CMP and offset printing paper and decreased material costs, specifically lower average unit purchase costs of recycled paper board and white scrap paper in the first nine months of 2020. Costs of sales per tonne for regular CMP, light-weight CMP, offset printing paper, tissue paper products were, $363, $339, $476, and $1,040, respectively, for the first nine months of 2020 compared to $394, $389, $497, and $1,244, respectively, for the same period of last year.

Total gross profit decreased by $3.1 million, or 38.7%, to $5.0 million for the first nine months of 2020 from $8.1 million for the same period of last year. Overall gross margin decreased by 2.4 percentage points to 7.2% for the first nine months of 2020 from 9.6% for the same period of last year. Gross margins for regular CMP, light-weight CMP, offset printing paper, tissue paper products and face mask products were 7.3%, 11.2%, 19.7%, -24.8% and 49.5%, respectively, for the first nine months of 2020, compared to 8.4%, 7.1%, 29.8%, -27.0% and nil, respectively, for the same period of last year.

Selling, General and Administrative Expenses

SG&A expenses increased by $1.0 million, or 13.9%, to $8.4 million for the first nine months of 2020 from $7.4 million for the same period of last year. As a percentage of total revenue, SG&A expenses was 12.3% for the first nine months of 2020, compared to 8.8% for the same period of last year.

Loss from Operations

Loss from operations increased by $4.2 million, or 593.4%, to $3.5 million for the first nine months of 2020 from income from operations of $0.7 million for the same period of last year. Operating loss margin was 5.1% for the first nine months of 2020, compared to operating margin of 0.8% for the same period of last year.

Net Loss

Net loss increased by $4 million, or 6110.9%, to $3.9 million, or loss per basic and diluted share of $0.15, for the first nine months of 2020,  compared to net income of $0.07 million, or earnings per basic and diluted share of $0.003, for the same period of last year.

EBITDA

EBITDA decreased by $3.5 million, or 32.6%, to $7.2 million for the first nine months of 2020 from $10.7 million for the same period of last year.

Note 1: Non-GAAP Financial Measures

In addition to our U.S. GAAP results, this press release includes a discussion of EBITDA, a non-GAAP financial measure as defined by the Securities and Exchange Commission (“SEC”). The Company defines EBITDA as net income before interest, income taxes, depreciation and amortization. EBITDA is a key measure used by management to evaluate our results and make strategic decisions. Management believes this measure is useful to investors because it is an indicator of operational performance. Because not all companies use identical calculations, the Company’s presentation of EBITDA may not be comparable to similarly titled measures of other companies, and should not be viewed as an alternative to measures of financial performance or changes in cash flows calculated in accordance with the U.S. GAAP.


Reconciliation of Net Income to EBITDA


(Amounts expressed in US$)


 For the Nine Months Ended September 30,


 ($ millions)


2020


2019

 Net income (loss)

-3.94

0.07

 Add: Income tax

0.58

-0.21

         Net interest expense

-0.74

-0.73

         Depreciation and amortization

11.30

11.55

 EBITDA


7.20


10.68

Cash, Liquidity and Financial Position

As of September 30, 2020, the Company had cash and bank balances, short-term debt (including bank loans, current portion of long-term loans from credit union and related party loans), and long-term debt (including loan from credit union) of $8.21 million, $10.77 million and $5.39 million, respectively, compared to $5.84 million, $8.31 million and $7.37 million, respectively, at the end of 2019.

Net accounts receivable was $3.47 million as of September 30, 2020, compared to $3.12 million as of December 31, 2019. Net inventory was $8.58 million as of September 30, 2020, compared to $1.61 million at the end of 2019. As of September 30, 2020, the Company had current assets of $30.41 million and current liabilities of $16.86 million, resulting in a working capital of $13.55 million. This was compared to current assets of $24.04 million and current liabilities of $16.84 million, resulting in a working capital of $7.21 million at the end of 2019.

Net cash provided by operating activities was $2.37 million for the first nine months of 2020, compared to net cash used in operating activities of $4.60 million for the same period of last year. Net cash used in investing activities was $2.57 million for the first nine months of 2020, compared to $6.45 million for the same period of last year. Net cash provided by financing activities was $2.24 million for the first nine months of 2020, compared to net cash used in financing activities of $5.22 million for the same period of last year.

Recent development

On July 7, 2020, the Company updated its non-medical single-use face masks business and announced that it recognized revenue of RMB6.73 million through June 30, 2020 from sale of 6.28 million pieces non-medical single-use face masks since launch of the production line at the end of April 2020.

On September 24, 2020, the Company announced that it was in advanced negotiations with one of its Top 5 customers, based in Shandong Province, for orders of paper products and that the two parties will further cooperate on product supply and purchase in the coming quarters and definitive new contracts are expected to be signed by the end of the year.

Earnings Conference Call

The Company’s management will host a conference call to discuss its third quarter 2020 financial results at 8:00 am US Eastern Time on Friday, November 13, 2020. To attend the conference call, please use the information below.

Date/Time: 8:00 am US Eastern Time (5:00 am US Pacific Time/9:00 pm Beijing Time) on Friday, November 13, 2020

Conference Title: IT Tech Packaging, Inc. Third Quarter 2020 Earnings Conference Call

Conference ID: 7992118

To attend the conference call, please register in advance of the conference using the link: http://apac.directeventreg.com/registration/event/7992118 to complete the online registration at least 15 minutes prior to the start of the call. Upon registering, the conference access information including participant dial-in numbers, a Direct Event passcode and a registrant ID will be provided to you via an email.

This conference call will be broadcast live on the Internet and can be accessed by all interested parties at  https://edge.media-server.com/mmc/p/5b72a65n  . Please access the link at least 15 minutes prior to the start of the call to register, download, and install any necessary audio software.

A playback will be available through 11:00 am ET on November 13, 2020 to 7:59 am ET on November 21, 2020. To listen, please dial+1-855-452-5696 if calling from the United States, or +61-281-990-299 if calling internationally. Use the conference ID 7992118 to access the replay.

About IT Tech Packaging, Inc.

Founded in 1996, IT Tech Packaging, Inc. is a leading manufacturer and distributor of diversified paper products and single-use face masks in North China. Using recycled paper as its primary raw material (with the exception of its tissue paper products), ITP produces and distributes three categories of paper products: corrugating medium paper, offset printing paper and tissue paper products. With production based in Baoding and Xingtai in North China’sHebei Province, ITP is located strategically close to the Beijing and Tianjin region, home to a growing base of industrial and manufacturing activities and one of the largest markets for paper products consumption in the country. ITP has been listed on the NYSE American since December 2009. For more information, please visit: http://www.itpackaging.cn/ .

Safe Harbor Statements

This press release may contain forward-looking statements. These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those projected or anticipated, including risks outlined in the Company’s public filings with the Securities and Exchange Commission, including the Company’s latest annual report on Form 10-K. All information provided in this press release speaks as of the date hereof. Except as otherwise required by law, the Company undertakes no obligation to update or revise its forward-looking statements.

For more information, please contact:

At the Company
Email: [email protected]
Tel: +86 0312 8698215

Investor Relations:
EverGreen Consulting Inc.
Janice Wang
+86-13811768559
+1-908-510-2351
Email: [email protected]

 


IT TECH PACKAGING, INC.


CONDENSED CONSOLIDATED BALANCE SHEETS


AS OF SEPTEMBER 30, 2020 AND DECEMBER 31, 2019


(Unaudited)


September 30,


December 31,


2020


2019


ASSETS

Current Assets

Cash and bank balances

$

8,209,905

$

5,837,745

Restricted cash

–

–

Accounts receivable (net of allowance for doubtful accounts of $64,435 and $59,922 as of September 30, 2020 and December 2019, respectively)

3,472,374

3,119,311

Inventories

8,582,912

1,607,463

Prepayments and other current assets

9,930,262

11,613,241

Due from related parties

215,192

1,863,479


Total current assets

30,410,645

24,041,239

Prepayment on property, plant and equipment

2,936,814

1,433,445

Finance lease right-of-use assets, net

2,336,399

–

Property, plant, and equipment, net

142,783,813

151,616,852

Value-added tax recoverable

2,497,129

2,621,841

Deferred tax asset non-current

12,365,164

10,485,053


Total Assets

$

193,329,964

$

190,198,430


LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities

Short-term bank loans

$

6,314,151

$

6,163,814

Current portion of long-term loans from credit union

3,803,175

1,605,459

Lease liability

168,546

–

Accounts payable

308,611

250,486

Advance from customers

179,491

98,311

Notes payable

–

–

Due to related parties

657,433

539,985

Accrued payroll and employee benefits

254,887

291,924

Other payables and accrued liabilities

4,573,972

6,503,010

Income taxes payable

599,782

1,382,471


Total current liabilities

16,860,048

16,835,460

Loans from credit union

5,389,054

7,367,908

Deferred gain on sale-leaseback

406,767

–

Lease liability – non-current

385,650

–

Derivative liability

1,199,585

–

Total liabilities (including amounts of the consolidated VIE without recourse to the Company of $17,636,464 and $19,558,568 as of September 30, 2020 and December 31, 2019, respectively)

24,241,104

24,203,368


Commitments and Contingencies

Stockholders’ Equity

28,515

22,055

Additional paid-in capital

53,974,869

51,155,174

Statutory earnings reserve

6,080,574

6,080,574

Accumulated other comprehensive loss

(1,852,602)

(6,057,537)

Retained earnings

110,857,504

114,794,796


Total stockholders’ equity

169,088,860

165,995,062


Total Liabilities and Stockholders’ Equity

$

193,329,964

$

190,198,430

  


IT TECH PACKAGING, INC.


CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME


FOR THE THREE AND
NINE
 MONTHS ENDED
SEPTEMBER
 30, 2020 AND 2019


(Unaudited)


Three Months Ended


Nine Months Ended


September 30,


September 30,


2020


2019


2020


2019

Revenues

$

33,357,451

$

32,937,917

$

68,463,575

$

84,008,157

Cost of sales

(30,789,899)

(27,563,185)

(63,506,913)

(75,917,762)


Gross Profit

2,567,551

5,374,732

4,956,662

8,090,395

Selling, general and administrative expenses

(2,390,920)

(2,024,547)

(8,445,356)

(7,413,879)

Gain on acquisition of a subsidiary

–

(879)

–

30,518


Income (Loss) from Operations

176,631

3,349,306

(3,488,694)

707,034


Other Income (Expense):

Interest income

8,544

1,413

23,785

61,787

Subsidy income

61,152

(2,800)

203,171

233,488

Interest expense

(258,438)

(236,987)

(744,592)

(731,027)

Loss on derivative liability

(482,515)

(510,380)


(Loss) Income before Income Taxes

(494,626)

3,110,932

(4,516,710)

271,282


Provision for Income Taxes

(26,348)

(772,905)

579,418

(205,780)


Net (Loss) Income

(520,974)

2,338,027

(3,937,292)

65,502


Other Comprehensive Income (Loss)

Foreign currency translation adjustment

6,670,510

(4,810,379)

4,204,935

(5,065,382)


Total Comprehensive Income (Loss)

$

6,149,536

$

(2,472,352)

$

267,643

$

(4,999,880)


(Losses) Earnings Per Share:


Basic and Diluted (Losses) Earnings per Share

$

(0.02)

$

0.11

$

(0.15)

$

0.003


Outstanding – Basic and Diluted

25,816,354

22,028,171

25,816,354

22,028,171

 


IT TECH PACKAGING, INC.


CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS


FOR THE
NINE
 MONTHS ENDED
SEPTEMBER
 30, 2020 AND 2019


(Unaudited)


Nine Months Ended


September 30,


2020


2019


Cash Flows from Operating Activities:

Net income

$

(3,937,292)

$

65,502

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization

11,301,703

11,547,650

Loss on derivative liability

510,380

–

Loss from disposal and impairment of property, plant and equipment

–

–

(Recovery from) Allowance for bad debts

2,973

(339)

Share-based compensation and expenses

1,242,000

–

Gain on acquisition of a subsidiary

(30,518)

Deferred tax

(1,582,754)

(1,853,728)

Changes in operating assets and liabilities:

Accounts receivable

(272,857)

16,894

Prepayments and other current assets

2,099,669

185,780

Inventories

(6,758,500)

(4,307,754)

Accounts payable

50,683

254,749

Advance from customers

76,763

85,993

Notes payable

–

(3,648,250)

Related parties

1,767,888

367,277

Accrued payroll and employee benefits

(43,025)

33,334

Other payables and accrued liabilities

(1,292,657)

726,564

Income taxes payable

(795,487)

1,155,880


Net Cash Provided by Operating Activities

2,369,487

4,599,034


Cash Flows from Investing Activities:

Purchases of property, plant and equipment

(3,144,261)

(4,917,650)

Proceeds from sale of property, plant and equipment

572,312

Acquisition of a subsidiary

–

(1,531,531)


Net Cash Used in Investing Activities

(2,571,949)

(6,449,181)


Cash Flows from Financing Activities:

Proceeds from issuance of shares and warrants, net

2,273,360

–

Proceeds from short term bank loans

–

3,940,110

Proceeds from credit union loans

–

2,334,880

Repayment of bank loans

–

(11,499,285)

Payment of capital lease obligation

(32,317)


Net Cash Provided by (Used in) Financing Activities

2,241,043

(5,224,295)


Effect of Exchange Rate Changes on Cash and Cash Equivalents

333,579

(237,122)


Net Increase (Decrease) in Cash and Cash Equivalents

2,372,160

(7,311,564)


Cash, Cash Equivalents and Restricted Cash – Beginning of Period

5,837,745

12,117,425


Cash, Cash Equivalents and Restricted Cash – End of Period

$

8,209,905

$

4,805,861


Supplemental Disclosure of Cash Flow Information:

Cash paid for interest, net of capitalized interest cost

$

509,783

$

659,613

Cash paid for income taxes

$

1,784,107

$

888,881

Cash and bank balances

8,209,905

4,805,861

Restricted cash

–

–


Total cash, cash equivalents and restricted cash shown in the statement of cash flows

8,209,905

4,805,861

Cision View original content:http://www.prnewswire.com/news-releases/it-tech-packaging-inc-announces-third-quarter-2020-financial-results-301172087.html

SOURCE IT Tech Packaging, Inc.